Cellectis (NASDAQ:CLLS) Research Coverage Started at StockNews.com

StockNews.com assumed coverage on shares of Cellectis (NASDAQ:CLLS) in a research note issued to investors on Thursday. The brokerage issued a sell rating on the biotechnology company’s stock.

Separately, Barclays reduced their target price on shares of Cellectis from $7.00 to $5.00 and set an “overweight” rating for the company in a report on Tuesday, November 5th.

Cellectis Stock Down 2.0 %

Shares of CLLS stock opened at $1.48 on Thursday. The company has a debt-to-equity ratio of 0.48, a quick ratio of 1.78 and a current ratio of 1.78. The stock has a market cap of $82.26 million, a PE ratio of -1.14 and a beta of 3.08. The business’s fifty day moving average is $1.83 and its 200-day moving average is $2.00. Cellectis has a 1 year low of $1.41 and a 1 year high of $3.38.

Cellectis (NASDAQ:CLLS) last issued its quarterly earnings results on Monday, November 4th. The biotechnology company reported ($0.23) EPS for the quarter, missing the consensus estimate of ($0.20) by ($0.03). Cellectis had a negative return on equity of 74.55% and a negative net margin of 234.39%. The business had revenue of $18.05 million during the quarter, compared to the consensus estimate of $5.00 million. During the same quarter last year, the firm posted ($0.31) earnings per share. Equities analysts expect that Cellectis will post -0.46 earnings per share for the current fiscal year.

Institutional Trading of Cellectis

Hedge funds have recently bought and sold shares of the company. XTX Topco Ltd acquired a new stake in shares of Cellectis during the second quarter valued at approximately $29,000. First Affirmative Financial Network purchased a new position in Cellectis during the 3rd quarter worth approximately $45,000. Finally, Long Focus Capital Management LLC grew its position in Cellectis by 2.9% during the 2nd quarter. Long Focus Capital Management LLC now owns 4,617,293 shares of the biotechnology company’s stock worth $8,634,000 after purchasing an additional 130,000 shares in the last quarter. 63.90% of the stock is owned by hedge funds and other institutional investors.

Cellectis Company Profile

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.